Reported $402 million in preliminary* full-year 2022 global net VYVGART sales
ADHERE topline results now expected in second quarter of 2023; Stage B enrollment has surpassed projected target of 130 patients
Registrational trial of efgartigimod in thyroid eye disease (TED) to start in 2023; additional proof-of-concept trials to start in ANCA-associated vasculitis and antibody mediated rejection (AMR)
Submission for marketing approval in Japan of VYVGART for immune thrombocytopenia (ITP) expected in mid-2023
https://finance.yahoo.com/news/argenx-highlights-2023-strategic-priorities-060000802.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.